What is HistoSonics?
Headquartered in Minnesota, HistoSonics is redefining the standard of care for tumor treatment through its novel histotripsy technology. Unlike traditional surgical interventions, radiation, or chemotherapy, the company's platform utilizes focused ultrasound to liquefy targeted tissue at a sub-cellular level without the need for incisions or needles. This approach minimizes patient trauma and side effects, positioning HistoSonics as a disruptive force within the medical device sector. The company's flagship Edison system represents a significant leap forward in precision medicine, allowing physicians to monitor and execute tumor destruction in real-time, thereby enhancing procedural accuracy and patient outcomes.
How much funding has HistoSonics raised?
HistoSonics has raised a total of $333.9M across 10 funding rounds:
Debt
$1.5M
Debt
$3M
Series B
$8.3M
Series C
$54M
Other Financing Round
$40M
Other Financing Round
$85M
Debt
$15M
Series D
$102M
Debt (2014): $1.5M supported by Venture Investors, Fletcher Spaght Ventures, and Hatteras Venture Partners
Debt (2015): $3M featuring Grand Angels
Series B (2017): $8.3M, investors not publicly disclosed
Series C (2019): $54M with participation from Varian Medical Systems, Venture Investors, State of Wisconsin - Investment Board, Fred Moll, Lumira Ventures, and JJDC
Other Financing Round (2020): $40M led by Venture Investors LLC, Yonjin Venture LLC, Johnson & Johnson Inc, Lumira Capital, Varian Medical Systems Inc, and State of Wisconsin - Investment Board
Other Financing Round (2022): $85M supported by Venture Investors, Johnson & Johnson Innovation, and Lumira Ventures
Debt (2022): $15M featuring Signature Bank
Series D (2024): $102M backed by HealthQuest Capital, Venture Investors, and Alpha Wave Ventures
Key Investors in HistoSonics
HealthQuest Capital
HealthQuest Capital provides growth capital to companies that are transforming healthcare through innovations in medical devices, technologies, and diagnostics.
Venture Investors
Venture Investors Health Fund is dedicated to shaping the future of healthcare by investing in groundbreaking innovations and university spinouts.
Alpha Wave Ventures
Alpha Wave Ventures is a research and development-focused firm that supports high-growth companies within the innovation ecosystem.
What's next for HistoSonics?
With the successful completion of this latest financing round, HistoSonics is well-positioned to accelerate the commercial adoption of its Edison Histotripsy System. The strategic focus will likely shift toward broadening the clinical indications for its technology beyond liver tumors, potentially addressing a wider range of oncological conditions. Furthermore, the company is expected to leverage its robust investor network to strengthen its market presence and operational infrastructure. As the healthcare industry increasingly prioritizes non-invasive, patient-centric solutions, HistoSonics remains at the forefront of medical innovation, poised to transform the landscape of interventional oncology through continued clinical validation and strategic market expansion.
See full HistoSonics company page
